Venatorx Pharmaceuticals today announced that it joined the Alliance for Biosecurity, a coalition of biopharmaceutical companies – along with laboratory and academic partners – that promotes a strong public-private partnership in order to ensure the medical countermeasures that protect public health are effective and readily available.
CARB-X is awarding Venatorx Pharmaceuticals up to US$4.1 million in non-dilutive funding, with the possibility of up to an additional US$8.9 million if certain project milestones are met, to develop a new class of oral antibiotics to treat infections caused by multi-drug-resistant (MDR) Neisseria gonorrhoeae.
With more than 20 years’ experience, Dr. Larsen is globally recognized as a leader in the area of public health preparedness. At Venatorx, Dr. Larsen will help translate Venatorx’s rich internal programs toward strategic public and private partnerships, and will help identify new growth opportunities for Venatorx.
Venatorx Pharmaceuticals has initiated enrollment in its Phase 3 trial of cefepime/VNRX-5133 in patients with complicated urinary tract infections (cUTIs). This Phase 3 clinical trial (ClinicalTrials.gov - NCT03840148) is a global randomized, double-blind, active controlled, non-inferiority study evaluating the efficacy, safety, and tolerability of cefepime/VNRX-5133 in adults with cUTI, including acute pyelonephritis. The trial will assess the safety and efficacy of cefepime/VNRX-5133 as compared with that of meropenem using clinical cure and microbiological eradication as the primary composite efficacy endpoint. Venatorx expects to enroll 582 patients for this study, and top-line results are expected by the end of 2020.
Venatorx Pharmaceuticals added pharmaceutical industry veterans, Jennifer Ellis, Dr. Paul McGovern and Lauren P. Tornetta, to its development team. These appointments come as the Company continues to advance its portfolio of antibacterial and antiviral assets through their respective pre-clinical and clinical milestones.
Venatorx Pharmaceuticals today announced that it was named one of the “2019 Best Places to Work” in the Greater Philadelphia area by the Philadelphia Business Journal for the second year in a row. Headquartered in the Philadelphia suburbs of Malvern, Pennsylvania, Venatorx has nearly doubled its headcount over the past year and is actively seeking motivated, passionate and entrepreneurial-minded professionals for open positions in Quality Assurance, Operations, Discovery, and Development to support its aggressive strategic growth plan.
The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) will collaborate with the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA) and Venatorx Pharmaceuticals, Inc. of Malvern, Pennsylvania, to develop a novel antibiotic to treat infections caused by bacteria resistant to currently available agents.
VenatoRx Pharmaceuticals' founders, Christopher J. Burns, Ph.D., Daniel C. Pevear, Ph.D., and Luigi Xerri, Ph.D., received the Entrepreneur Of The Year® 2019 Award in the Health and Life Sciences category in Greater Philadelphia.
Venatorx Pharmaceuticals will present ten posters featuring its two development-stage products, cefepime/VNRX-5133 and ceftibuten/VNRX-7145, at ASM Microbe 2019 to be held June 20-24 in San Francisco, CA. Venatorx will also present an overview if its antibacterial agents portfolio during the Pharma Pipeline Update, concentrating on its orally bioavailable beta-lactamase inhibitor, VNRX-7145, during the New Agents Discovery Summary Session.
Venatorx Pharmaceuticals will have 12 poster presentations at ECCMID 2019 featuring cefepime/VNRX-5133 and ceftibuten/VNRX-7145.
Dr. Wittmer has more than 20 years’ experience and a demonstrated track record in leading development from early stages through to licensing, registration and commercialization of new therapeutics. In her role at Venatorx, Dr. Wittmer will oversee nonclinical and clinical development, as well as global regulatory affairs.
President and CEO, Christopher J. Burns, Ph.D., will present the Company's novel, orally-bioavailable beta-lactamase inhibitor, VNRX-7145, during the First Time Disclosure of Clinical Candidates at the American Chemical Society (ACS) National Meeting. The presentation entitled, “Discovery of VNRX-7145: A broad-spectrum orally bioavailable beta-lactamase inhibitor (BLI) for highly resistant bacterial infections (“superbugs”)” is scheduled for Wednesday, April 3, 2019 at 10:35am ET in the Valencia Ballroom A at the Orange County Convention Center in Orlando, FL.
Recognition honors a CEO who has demonstrated visionary leadership and active participation to advance the life sciences and biotech industry.
The objective of this R01 grant is to provide tools that can facilitate therapeutic discovery for Gram-negative bacterial pathogens, including carbapenem-resistant Enterobacteriaceae (CRE), multi-drug resistant (MDR) Acinetobacter baumannii and/or MDR Pseudomonas aeruginosa. This initiative will also support Venatorx’s discovery programs targeting novel antibacterial agents.
Chief Business Officer, Tony Meehan, MBA, PhD, will present attendees with an overview of Venatorx's pipeline and unique operating model on Monday, February 11, 2019 at 3:30pm ET in the Gramercy room at the New York Marriott Marquis.
The Antimicrobials Working Group (AWG) announced the addition of Venatorx Pharmaceuticals to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 15 antimicrobial drug companies.